XML 11 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Cover Page - USD ($)
 12 Months Ended
Dec. 31, 2024
Feb. 24, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Registrant Name CATALYST PHARMACEUTICALS, INC.    
Entity Central Index Key 0001369568    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Shell Company false    
Entity Filer Category Large Accelerated Filer    
Trading Symbol CPRX    
Entity Emerging Growth Company false    
Entity Small Business false    
Entity Address, State or Province FL    
Entity Interactive Data Current Yes    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Security Exchange Name NASDAQ    
Entity Common Stock, Shares Outstanding   121,449,655  
Entity Tax Identification Number 76-0837053    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 355 Alhambra Circle    
Entity Address, Address Line Two Suite 801    
Entity Address, City or Town Coral Gables    
Entity Address, Postal Zip Code 33134    
City Area Code 305    
Local Phone Number 420-3200    
Document Annual Report true    
Document Transition Report false    
Entity File Number 001-33057    
Entity Public Float     $ 1,720,853,867
ICFR Auditor Attestation Flag true    
Documents Incorporated by Reference [Text Block]

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Definitive Proxy Statement to be filed for Catalyst Pharmaceuticals, Inc.'s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.

    
Auditor Name GRANT THORNTON LLP    
Auditor Firm ID 248    
Auditor Location Miami, Florida    
Document Financial Statement Error Correction [Flag] false    
Auditor Opinion [Text Block]

Opinion on internal control over financial reporting

We have audited the internal control over financial reporting of Catalyst Pharmaceuticals, Inc. (a Delaware corporation) and subsidiary (the “Company”) as of December 31, 2024, based on criteria established in the 2013 Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in the 2013 Internal Control—Integrated Framework issued by COSO.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated financial statements of the Company as of and for the year ended December 31, 2024, and our report dated February 26, 2025 expressed an unqualified opinion on those financial statements.